Literature DB >> 8402634

Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.

S A van Acker1, E E Voest, D B Beems, H T Madhuizen, J de Jong, A Bast, W J van der Vijgh.   

Abstract

Chronic doxorubicin-induced cardiotoxicity is believed to be caused by the formation of oxygen free radicals. Thus O-(beta-hydroxyethyl)-rutosides, a standardized flavonoid mixture (Venoruton) with iron chelating and radical scavenging activity, might provide protection. Therefore, we investigated the (cardio)protective effect of Venoruton (1.5 g/kg injected i.p. on days 1-5, 8-12, 15-19, and 22-26) in BALB/c mice treated with doxorubicin (4 mg/kg injected i.v. on days 1, 8, 15, and 22) compared with mice treated with doxorubicin alone. Saline-treated animals served as controls. No mortality was encountered in either of the groups; weight gain data suggest little general toxicity of this dose schedule. The basal frequency of the isolated right atria was increased in doxorubicin-pretreated animals as compared to control animals (468 +/- 22 and 366 +/- 20 beats/min, respectively). Venoruton coadministration diminished this increase (373 +/- 17 beats/min). The -log of the concentration giving 50% effect of l-isoprenaline on the right atrium was changed after doxorubicin pretreatment (8.33 +/- 0.04 versus 8.86 +/- 0.06 for control animals). Venoruton coadministration resulted in a smaller shift in the -log of the concentration giving 50% effect (8.51 +/- 0.10) than with doxorubicin alone. The extent of cardiotoxicity found in the functional studies was confirmed by histological scoring of heart ventricle damage. It can be concluded that Venoruton has the potential to protect against doxorubicin-induced cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402634

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

2.  Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction.

Authors:  M Y Maslov; V P Chacko; G A Hirsch; A Akki; M K Leppo; C Steenbergen; R G Weiss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-21       Impact factor: 4.733

3.  Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.

Authors:  Evert L de Beer; Antonio E Bottone; Maartje C van Rijk; Jolanda van der Velden; Emile E Voest
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

4.  Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

Authors:  S A van Acker; K Kramer; J A Grimbergen; D J van den Berg; W J van der Vijgh; A Bast
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

5.  Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.

Authors:  B C Hüsken; J de Jong; B Beekman; R C Onderwater; W J van der Vijgh; A Bast
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.